Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks that will double in 2026. On December 10, Clear Street raised the firm’s price target on Cullinan Therapeutics to $33 from $22 with a Buy ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cullinan Therapeutics Inc (Symbol: CGEM), where a total of 5,055 contracts have traded so ...

NADIM AHMED, the President and CEO of $CGEM ($CGEM), sold 8,400 shares of the company on 12-24-2024. We received data on the trade from a recent SEC filing. This was ...

CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncology and ...

Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates.